- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02581371
Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm
Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke
The aim of the present clinical phase IV study is to estimate the influence of Cerebrolysin in combination with standard therapy on the dynamics of recovery of the paretic upper limb in patients with acute ischemic stroke.
Each patient participates in the study for 176-190 days (approximately 6 months). The estimated duration of the study is 2 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rehabilitation programs and drug therapy in a stroke aimed, primarily, to the stimulation of the processes of neuroplasticity.
After the screening procedures the eligible patients get randomized in 1 of the 2 groups: either the group of a standard therapy in combination with Cerebrolysin infusions, or the group of a standard therapy in combination with placebo infusions.
The therapy consists of the 3 consecutive periods:
- st - 10 days of daily infusions of Cerebrolysin / placebo;
- nd - 7 days break;
- d - 10 days of daily infusions of Cerebrolysin / placebo.
All participants will attend 7 Visits of the study (Visits 0, 1-6) at 2 sites respectively:
- st - clinical center #1 - Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg
- nd - clinical center #2 - Clinical Institute of Brain, Ekaterinburg.
Patients will be transferred from the 1st site to the 2nd one at the moment of time between Visit 2 and Visit 3.
Patients will undergo traditional laboratory and clinical examination procedures and several specific ones such as scale NIHSS, modified Rankin scale, Barthel index, hand Frenchy assessments. All hand Frenchy assessments will be videotaped for later evaluation by an authorized researcher.
All participants will undergo the procedure of navigational transcranial magnetic stimulation of the brain NBS eXimia Nexstim with the use of an individual 3D brain model created on the Visit 0 MRI results basis.
Neither the patient nor the doctor will know whether they receive an investigational drug or placebo.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Andrey Avgustovich Belkin, Prof.,MD,PhD
- Phone Number: (343) 311-3381
- Email: clinic@neuro-clinic.ru
Study Contact Backup
- Name: Andrey Marisovich Alasheev, MD, PhD
- Phone Number: (343) 351-1535
- Email: director@sciencefiles.ru
Study Locations
-
-
Sverdlovsk region
-
Beryozovsky, Sverdlovsk region, Russian Federation, 620102
- Recruiting
- Clinical Institute of Brain
-
Contact:
- Andrey Avgustovich Belkin, Prof.,MD,PhD
- Phone Number: (343) 311-3381
- Email: clinic@neuro-clinic.ru
-
Principal Investigator:
- Andrey Avgustovich Belkin, Prof.,MD,PhD
-
Ekaterinburg, Sverdlovsk region, Russian Federation, 620102
- Recruiting
- Sverdlovsk Regional Clinical Hospital #1
-
Contact:
- Andrey Marisovich Alasheev, MD, PhD
- Phone Number: +7(905)800-43-02
- Email: director@sciencefiles.com
-
Principal Investigator:
- Andrey Marisovich Alasheev, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- A signed patient informed consent;
- Men and women at the age from 45 years to 75 years, inclusive;
- Confirmed (clinically and by MRI of the brain) diagnosis of acute ischemic stroke in the basin of the middle cerebral artery;
- The severity of the stroke from 5 to 24 points on a scale NIHSS;
- Hemiparesis, mainly affecting the upper limbs (not more than 2 points in the evaluation function of the affected hand using the test for hand Frenchay and not more than 2 points in the evaluation of the affected lower limb 6-point scale NIHSS);
- The time from the onset of the disease prior to the introduction of the drug for 72 hours;
- The willingness of patients of both sexes and their sexual partners with preserved reproductive function to use reliable methods of contraception, starting from the moment of inclusion in the study until the completion of participation in this clinical study.
Exclusion Criteria:
- The age of 45 years or older than 75 years;
- Known intolerance (including allergic reactions) Cerebrolysin, excipients of the investigational medication;
- Thrombolytic therapy;
- Signs of a hemorrhagic stroke;
- Impairment of consciousness (≥ 2 points during the evaluation under item 1A NIHSS);
- The presence of elements allowing to predict the resolution of neurological symptoms within 24 hours from the first symptoms;
- Stroke or transient ischemic attack in history;
- The score on the modified Rankin scale to a stroke more than 0 points;
- Concomitant therapy or neuroprotective nootropic drugs;
- New-onset seizures or epilepsy;
- Planned carotid endarterectomy or other operations for secondary prevention of stroke;
- Neurological disease or pathology of the neuromuscular system or any other disease that may affect the interpretation of study results;
- Systemic therapy with biological drugs, including interferon, inductors and/or cytokine/anti-cytokine (e.g., anti-TNF, anti-CD4, IL-10, IL-1, etc.) within 1 month prior to screening;
- Severe concomitant diseases, including cancer, which, in the opinion of the investigator, may affect the estimated parameters;
- Uncontrolled hypertension (SBP ≥ 220 mm Hg. CL. and/or DBP ≥ 120 mm Hg. article in repeated measurements at the screening visit);
- Uncontrolled angina, congestive heart failure or severe arrhythmia;
- The presence of chronic infection (hepatitis B, C or AIDS) in the active form.
- Severely impaired renal function or hepatic impairment (total bilirubin no more than 1.5 hvgn, the level of serum creatinine no more than 2.5 hugn and the levels of ALT, AST, GGT is not higher than 2.5 hvgn);
- Diseases of the blood;
- Mental illness, severe depression or suicide attempts in history;
- The a history of drug addiction, alcoholism and abuse of drugs;
- Contraindications to MRI: metal body, splinters, ferromagnetic implants (pacemakers, automatic dosing of drugs, implanted insulin pumps, artificial anus with a magnetic closure, artificial heart valves with metal elements), steel implants (clamps/clips on blood vessels, artificial joints, metal osteosynthesis devices), hearing AIDS;
- Participation in any other clinical study within 30 days prior to screening or simultaneous participation in other clinical studies;
- Pregnancy, breastfeeding or planning a pregnancy;
- Women and men with preserved reproductive potential who refuse to use effective methods of contraception throughout the study;
- Life expectancy less than 1 year;
- Any disease or circumstances that, in the opinion of the investigator, may interfere with the subject participating in the study or in relation to which participation in the study may be dangerous for the subject;
Premature withdrowal criteria:
- The research subject may discontinue participation at any time without giving a reason;
- The researcher ahead of time to exclude the patient from the study in the following cases;
- The refusal of the subject from further participation in the study;
- Failure to comply with the subject rules of participation in the study;
- The reasons that emerged during the study and threatening the security of the subject, including those associated with taking study medication adverse events;
- The entities with during the study pregnancy;
- The application of the patient in the study period of any additional neuroprotective and nootropic drugs, drugs from the group of correctors of cerebral blood flow;
- Other reasons arising in the course of the study and prevent the realization of the study according to the Protocol;
- Repeated stroke in the course of the study;
- Subjects who are lost to observation, also belong to prematurely withdrawn from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cerebrolysin infusion
Cerebrolysin, solution for injection, 10 ml vials.
Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
|
Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
Other Names:
|
Placebo Comparator: Placebo infusion
Sodium chloride 0.9%, solution for infusion, 100 ml.
Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
|
Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall dynamics of the hand function assessed by the Frenchay Arm Test
Time Frame: 6 months
|
Visit 5 data comparison with Visit 0 data
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dynamics of the hand function assessed by the Frenchay Arm Test
Time Frame: 6 months
|
Visits 2,3,4 data comparison with Visit 0 data
|
6 months
|
Dynamics of the grades on the NIHSS scale
Time Frame: 6 months
|
Visits 2,3,4,5 data comparison with Visit 0 data
|
6 months
|
Dynamics of the grades on the modified Rankin scale
Time Frame: 6 months
|
Visits 2,3,4,5 data comparison with Visit 0 data
|
6 months
|
Dynamics of the Barthel index changes
Time Frame: 6 months
|
Visits 2,3,4,5 data comparison with Visit 0 data
|
6 months
|
Dynamics of the cerebral infarction volume decrease according the 3D MRI data
Time Frame: 6 months
|
6 months
|
|
Dynamics of the hemispheres cortex topology of palms motor centers according to navigated transcranial stimulation of the brain (NBS)
Time Frame: 6 months
|
Visit 4, 5 data comparison with Visit 3 data
|
6 months
|
Dynamics of motor response threshold based on the results of navigated transcranial stimulation of the brain (NBS)
Time Frame: 6 months
|
6 months
|
|
Dynamics of the amplitude of motor responses
Time Frame: 6 months
|
6 months
|
|
Dynamics of the latency of motor responses
Time Frame: 6 months
|
6 months
|
|
Frequency, nature and severity of adverse events.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Investigators
- Study Director: Andrey Avgustovich Belkin, Prof.,MD,PhD, Clinical Institute of Brain
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Infarction
- Brain Infarction
- Stroke
- Ischemic Stroke
- Ischemia
- Cerebral Infarction
- Physiological Effects of Drugs
- Neuroprotective Agents
- Protective Agents
- Nootropic Agents
- Cerebrolysin
Other Study ID Numbers
- COMRIS-ARM-C
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Cerebrolysin infusion
-
Ever Neuro Pharma GmbHacromion GmbHCompleted
-
Samsung Medical CenterCompletedCerebrolysinKorea, Republic of
-
Mansoura University Children HospitalCompleted
-
Kwong Wah HospitalCompletedSubarachnoid Hemorrhage | Delayed Cerebral Ischemia | Intracranial Aneurysm | Delayed Ischemic Neurological DeficitChina
-
Sahar M.A. Hassanein, MDCompletedHypoxic-Ischemic EncephalopathyEgypt
-
Ain Shams UniversityUnknownMental Handicap | Cerebral Palsy Children | Children With Traumatic Brain Injury | Delayed Speech DevelopmentEgypt
-
Mansoura University Children HospitalCompletedCerebral Palsy | Infant Development | Preterm InfantEgypt
-
Clinical Institute of the Brain, RussiaEver Neuro Pharma GmbH; Nycomed; VeropharmCompleted
-
Hospital Universitario Dr. Jose E. GonzalezEver Neuro Pharma GmbHRecruitingDiabetes Mellitus, Type 2 | Ischemic Stroke, Acute | Blood Brain BarrierMexico
-
Chang Gung Memorial HospitalNot yet recruiting